{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04692831",
            "orgStudyIdInfo": {
                "id": "20-275"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Testing a New Imaging Agent to Identify Cancer",
            "officialTitle": "Imaging of HER2-expressing Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "testing-a-new-imaging-agent-to-identify-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2020-11-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-30",
            "studyFirstSubmitQcDate": "2020-12-30",
            "studyFirstPostDateStruct": {
                "date": "2021-01-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institutes of Health (NIH)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer."
        },
        "conditionsModule": {
            "conditions": [
                "HER-2 Positive Malignant Carcinoma of Breast",
                "HER-2 Protein Overexpression",
                "HER2-positive Metastatic Breast Cancer"
            ],
            "keywords": [
                "HER-2 Positive Malignant Carcinoma of Breast",
                "HER-2 Protein Overexpression",
                "HER2-positive Metastatic Breast Cancer",
                "3+ HER2 IHC",
                "2+ HER2 IHC",
                "20-275",
                "Memorial Sloan Kettering Cancer Center",
                "HER2-positive primary malignancy",
                "Zr-ss-Pertuzumab"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "This protocol will perform a first-in-human imaging trial of 89Zr-ss-pertuzumab.",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HER2-positive malignancy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will have a diagnosis of HER2-positive malignancy",
                    "interventionNames": [
                        "Combination Product: 89Zr-ss-pertuzumab PET/CT"
                    ]
                },
                {
                    "label": "HER2-low malignancy",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will have a diagnosis of HER2-low malignancy",
                    "interventionNames": [
                        "Combination Product: 89Zr-ss-pertuzumab PET/CT"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "COMBINATION_PRODUCT",
                    "name": "89Zr-ss-pertuzumab PET/CT",
                    "description": "Patients will receive 89Zr-ss-pertuzumab. 89Zr-ss-pertuzumab PET/CT images will be reconstructed using iterative reconstruction and displayed in multiplanar reconstruction. In the event that 89Zr-ss-pertuzumab is unavailable, randomly labelled 89Zr-pertuzumab PET will be allowed to make HER2 PET imaging available for our patients. Once 89Zr-ss-pertuzumab is available, then patients will be imaged with 89Zr-ss-pertuzumab and randomly labelled 89Zr-pertuzumab will no longer be used.",
                    "armGroupLabels": [
                        "HER2-low malignancy",
                        "HER2-positive malignancy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluate clinical safety of 89Zr-ss-pertuzumab",
                    "description": "CTCAE Version 5 will be utilized for toxicity evaluation",
                    "timeFrame": "Up to 20 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Biopsy proven HER2-positive or HER2-low primary malignancy or metastatic disease\n\nNote: HER2 positivity is defined according to American Society of Clinical Oncology guidelines or ERBB2 amplification on next generation sequencing Note: HER2-low is defined as low HER2 expression, with immunohistochemistry (IHC) 1+ or IHC 2+ and in situ hybridization \\[ISH\\]-negative, including FISH.\n\n* Biopsy proven primary malignancy or metastatic disease\n* At least one malignant lesion on CT, MR, or FDG PET/CT within 60 days of protocol enrollment\n* Age 18 years or greater\n* ECOG performance of 0-2\n\nExclusion Criteria:\n\n* Creatinine \\> 2 times normal limit (obtained with 8 weeks of enrollment)\n* AST/ALT \\> 2 times normal limit (obtained with 8 weeks of enrollment)\n* Life expectancy \\< 3 months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT due to weight limits (over 450 pounds)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Randy Yeh, MD",
                    "role": "CONTACT",
                    "phone": "212-639-3776",
                    "email": "yehr@mskcc.org"
                },
                {
                    "name": "Jason Lewis, PhD",
                    "role": "CONTACT",
                    "phone": "646-888-3038",
                    "email": "lewisj2@mskcc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Randy Yeh, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "PATTY AND GEORGE HOAG CANCER CENTER (Data or Specimen Analysis Only)",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Newport Beach",
                    "state": "California",
                    "zip": "92663",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Gary Ulaner, MD, PhD",
                            "role": "CONTACT",
                            "phone": "949-722-6237"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.61891,
                        "lon": -117.92895
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (Limited protocol activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Bergen (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Montvale",
                    "state": "New Jersey",
                    "zip": "07645",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.04676,
                        "lon": -74.02292
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center (All Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (Limited Protocol Activites)",
                    "status": "RECRUITING",
                    "city": "Rockville Centre",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Randy Yeh, MD",
                            "role": "CONTACT",
                            "phone": "212-639-3776"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.65871,
                        "lon": -73.64124
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Carcinoma of Breast",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000485206",
                    "term": "Pertuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M289243",
                    "name": "Pertuzumab",
                    "asFound": "Temozolomide",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}